Education
About Us
Working with TipRanks
Follow Us
Rapport Therapeutics, Inc. (RAPP)
NASDAQ:RAPP
RAPP Stock Chart & Stats
$26.81
-$0.34(-1.94%)
At close: 4:00 PM EST
$26.81
-$0.34(-1.94%)
Day’s Range― - ―
52-Week Range$6.43 - $42.27
Previous CloseN/A
Volume10.11K
Average Volume (3M)368.10K
Market Cap
$1.28B
Enterprise Value$625.30M
Total Cash (Recent Filing)$513.03M
Total Debt (Recent Filing)$11.87M
Price to Earnings (P/E)―
Beta1.65
Next Earnings
Mar 17, 2026EPS Estimate
-0.66Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.71
Shares Outstanding47,661,137
10 Day Avg. Volume361,742
30 Day Avg. Volume368,100
Financial Highlights & Ratios
PEG Ratio-0.47
Price to Book (P/B)12.05
Price to Sales (P/S)0.00
P/FCF Ratio-54.72
Enterprise Value/Market Cap0.49
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-5.90
Forecast
1Y Price Target
$54.60Price Target Upside103.66% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-3.54
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Development TimelineRefined development timeline to initiate the Phase 3 program earlier, paired with an extended maintenance window to reduce natural seizure variability, could improve the reliability and timeliness of pivotal efficacy readouts.
Clinical EfficacyPhase 2 data showed substantial reductions in long seizure episodes and clinical seizures, including cases of complete seizure freedom in highly drug‑resistant patients, indicating strong efficacy potential.
Pipeline DiversificationAdvancement of a long‑acting injectable formulation with IND‑enabling activities underway and reallocation to a selective α6β4 nicotinic receptor program for chronic pain and migraine broadens the pipeline and non‑opioid treatment opportunities.
Bears Say
Cognitive Safety ConcernPotential impacts on memory remain a safety concern that warrant ongoing monitoring as additional clinical data are gathered.
Mood And Psychiatric Safety RiskTargeting limbic brain circuits creates a risk of mood changes that will require real‑world experience to fully assess safety in patients with psychiatric comorbidities.
Pharmacokinetics And Dosing FlexibilityA relatively long half‑life may prolong the time to reach steady‑state and complicate dose adjustments, creating potential dosing and tolerability challenges.
RAPP FAQ
What was Rapport Therapeutics, Inc.’s price range in the past 12 months?
Rapport Therapeutics, Inc. lowest stock price was $6.43 and its highest was $42.27 in the past 12 months.
What is Rapport Therapeutics, Inc.’s market cap?
Rapport Therapeutics, Inc.’s market cap is $1.28B.
When is Rapport Therapeutics, Inc.’s upcoming earnings report date?
Rapport Therapeutics, Inc.’s upcoming earnings report date is Mar 17, 2026 which is in 58 days.
How were Rapport Therapeutics, Inc.’s earnings last quarter?
Rapport Therapeutics, Inc. released its earnings results on Nov 06, 2025. The company reported -$0.71 earnings per share for the quarter, beating the consensus estimate of -$0.775 by $0.065.
Is Rapport Therapeutics, Inc. overvalued?
According to Wall Street analysts Rapport Therapeutics, Inc.’s price is currently Undervalued.
Does Rapport Therapeutics, Inc. pay dividends?
Rapport Therapeutics, Inc. does not currently pay dividends.
What is Rapport Therapeutics, Inc.’s EPS estimate?
Rapport Therapeutics, Inc.’s EPS estimate is -0.66.
How many shares outstanding does Rapport Therapeutics, Inc. have?
Rapport Therapeutics, Inc. has 47,661,137 shares outstanding.
What happened to Rapport Therapeutics, Inc.’s price movement after its last earnings report?
Rapport Therapeutics, Inc. reported an EPS of -$0.71 in its last earnings report, beating expectations of -$0.775. Following the earnings report the stock price went down -3.095%.
Which hedge fund is a major shareholder of Rapport Therapeutics, Inc.?
Currently, no hedge funds are holding shares in RAPP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Rapport Therapeutics, Inc. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$54.60 (103.66% Upside)
$54.60 (103.66% Upside)
Blogger Sentiment
Bullish
RAPP Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 1.1M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▼ 3.4%
Last 30 Days ▲ 6.4%
Last 30 Days ▲ 6.4%
Technicals
SMA
Positive
20 days / 200 days
Momentum
114.30%
12-Months-Change
Fundamentals
Return on Equity
-23.41%
Trailing 12-Months
Asset Growth
61.66%
Trailing 12-Months
Company Description
Rapport Therapeutics, Inc.
Rapport Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company that focuses on the discovery and development of transformational small molecule medicines for patients suffering from central nervous system (CNS) disorders. Its lead product candidate is receptor associated protein (RAP)-219, an investigational small molecule that is designed to inhibit TARPy8-containing AMPARs with picomolar affinity for the treatment of focal epilepsy and other CNS disorders, including peripheral neuropathic pain and bipolar disorder. The company also develops RAP-199, a TARPy8 targeted molecule with differentiated chemical and pharmacokinetic properties; and nicotinic acetylcholine receptor (nAChR) programs, such as a6 nAChR to treat chronic pain and a9a10 nAChR for the treatment of hearing disorders. The company was formerly known as Precision Neuroscience NewCo, Inc. and changed its name to Rapport Therapeutics, Inc. in October 2022. Rapport Therapeutics, Inc. was incorporated in 2022 and is based in Boston, Massachusetts.
RAPP Stock 12 Month Forecast
Average Price Target
$54.60
▲(103.66% Upside)
Technical Analysis
Ownership Overview
Currently, No data available
---